Esplugues de Llobregat, Spain

Jaume Ruiz I Pol




Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jaume Ruiz I Pol: Innovator in Pharmaceutical Solutions

Introduction

Jaume Ruiz I Pol is a notable inventor based in Esplugues de Llobregat, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of otic inflammation. His innovative approach has led to the development of a unique composition that addresses this medical issue effectively.

Latest Patents

Jaume Ruiz I Pol holds a patent for "Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation." This pharmaceutical otic sterile preservative-free composition is formulated as a clear aqueous solution containing 0.01-0.10% (w/v) of Fluocinolone Acetonide. The composition may also include 0.1-0.8% of Ciprofloxacin or a pharmaceutically acceptable salt thereof, along with a nonionic surfactant, a tonicity adjusting agent, and a viscosity increasing agent. This invention is particularly useful for the prevention and/or treatment of otic inflammation, especially when accompanied by bacterial infection, and is designed for administration from single-use containers. He has 1 patent to his name.

Career Highlights

Jaume Ruiz I Pol is associated with Laboratorios Salvat, S.A., where he has been instrumental in advancing pharmaceutical formulations. His work focuses on creating effective solutions that enhance patient care and treatment outcomes.

Collaborations

One of his notable collaborators is Francisca Izquierdo Torres, with whom he has worked on various projects aimed at improving pharmaceutical products.

Conclusion

Jaume Ruiz I Pol's contributions to the field of pharmaceuticals, particularly through his innovative patent, highlight his commitment to improving healthcare solutions. His work continues to impact the treatment of otic inflammation positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…